Speculative Bullish Options Flow in AbbVie (ABBV) as Management Presents at Healthcare Conference -Susquehanna

Near-Term Bullish Options Activity in AbbVie (ABBV) Targets Upside Above $90 Amid Rally in Shares -Susuqehanna

Susquehanna options strategist Alison Edwards notes bullish options trading in AbbVie (NYSE: ABBV), as investors purchased 2600 Sep22 90 (.32d) calls for up to $0.70, targeting upside above $90 into end of next week.

AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study

AbbVie (NYSE: ABBV) today announced positive top-line results from the Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond or were intolerant to treatment with biologic DMARDs (bDMARDs).1 Results showed that after 12 weeks of treatment, both once-daily doses of upadacitinib (15 mg and 30 mg) met the study's primary endpoints of ACR20* and low disease activity (LDA)**.1 All ranked secondary endpoints were also achieved with both doses.1 Upadacitinib is not... More

Abbvie (ABBV): IPR Victory Translates Into A 36% PT Increase - Cowen

Cowen analyst, Steve Scala, reiterated his Outperform rating on shares of Abbvie (NYSE: ABBV) and raised his price target to $95 from $70 noting that last week's IPR victory targeting a Humira formulation patent is important leading the analyst to give ABBV the... More

AbbVie (ABBV) Declares $0.64 Quarterly Dividend; 3.1% Yield

AbbVie (NYSE: ABBV) declared a quarterly dividend of $0.64 per share, or $2.56 annualized.

The dividend will be payable on November 15, 2017, to stockholders of record on October 13, 2017, with an ex-dividend date of October 12, 2017.

The annual yield on the dividend is 3.1 percent.

For a... More

Abbvie (ABBV) PT Raised to $100 at Goldman Sachs

Goldman Sachs raised its price target on Abbvie (NYSE: ABBV) to $100.00 (from $85.00) while maintaining a Buy rating.

Analyst Jami Rubin says the bear thesis on Humira has been challenged following the news that there will be a difficult path for biosimilars to hit... More